Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
The cells may be systemically administered to treat osteoporosis, osteolysis, improve bone implant adherence, augment bone growth or bone repair, augment cartilage repair, and augment fat production.
The cells can differentiate into osteocytes, chondrocytes and adipocytes in the presense of the appropriate stimulus and environment.
The cells are "homing" cells, that is, cells injected systemically into the patient home to the bone marrow, unless specifically placed in another location.
The cells may be transformed with recombinant DNA for the expression of both reporter genes, and biological factors, such as growth factors.
Balian G, et al. Pluripotential bone marrow cell line and methods of using the same. US Patent 6,082,364 dated Jul 4 2000
